August 2012
-
Levo Therapeutics has announced that the FDA has granted Fast Track designation to its LV-101 intranasal carbetocin for the treatment of Prader-Willi syndrome (PWS). In December 2018, Levo said that it was initiating the CARE-PWS… Read more . . .
-
According to Seelos Therapeutics, the FDA has granted Fast Track designation to its SLS-002 intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder. The company also… Read more . . .
-
Savara has announced the appointment of Badrul Chowdhury, as Chief Medical Officer, a newly created position. From 2002-2018, Chowdhury was the Director of the FDA’s Division of Pulmonary, Allergy, and Rheumatology Products, Center for Drug Evaluation and… Read more . . .
-
French drug delivery device company Biocorp announced that it has entered into a 10-year strategic partnership with Vitrobio Pharma regarding manufacturing of a new intranasal polymeric product that the company says “acts as a barrier… Read more . . .
-
On November 1, 2019, Aquestive Therapeutics filed a citizen petition asking the FDA to stay approval of a 505(b)(2) NDA submitted by Neurelis in September 2018 for Valtoco diazepam nasal spray for the treatment of… Read more . . .
-
Insmed Incorporated has announced the appointment of Clementia Pharmaceuticals President and CEO Clarissa Desjardins to its board of directors and the promotions of Roger Adsett to Chief Operating Officer and Drayton Wise to Senior VP, Head of United… Read more . . .
-
According to Adherium, the company has received $1.1 million in a second round of secured debt note financing, and the subscriber for this round is new strategic investor Trudell Medical Limited, parent company of respiratory… Read more . . .
-
AZTherapies has named Ernest D. Penachio to the newly created position of VP of Manufacturing Operations and CMC to oversee clinical and pre-commercial manufacturing, scale-up, and CMC content development for the company’s ALZT-OP1 inhaled cromolyn/oral… Read more . . .
-
Device maker Iconovo and particle engineering specialist CrystecPharma have announced a non-exclusive collaboration agreement for development of dry powder inhalers. The companies say that they plan to develop engineered particles using CrystecPharma’s modified supercritical anti-solvent… Read more . . .
-
Many of the winners at this year’s CPhI Pharma Awards, held on November 5 at the 2019 CPhI Worldwide meeting in Frankfurt, Germany, offer significant expertise in inhaled and nasal drug delivery, including Lonza, which… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.